EthOss Regeneration
EthOss Regeneration is a UK medical device company that develops a 100% synthetic 65% β-TCP / 35% calcium sulphate bone graft material for dental implant surgery, sold via exclusive distributors in 65+ markets to clinicians and oral surgeons globally.
- Company typePrivate
- Founded2013
- HeadquartersSilsden, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What EthOss Regeneration does
EthOss Regeneration Ltd is a UK-based medical device company that develops and commercialises a 100% synthetic bone graft biomaterial for dental implant surgery. Founded in 2013 in West Yorkshire by dental surgeon Dr Peter Fairbairn and biomaterial specialist Dr Paul Harrison, the company's flagship product — EthOss Bone Graft Material — combines 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate in a syringe-applicator delivery format (0.25cc, 0.5cc, 1cc). The calcium sulphate component sets in situ to form a cell-occlusive barrier, eliminating the need for a separate collagen membrane, and the material is designed to be fully resorbed and replaced by host bone within 6–12 months. The company holds ISO 13485 and ISO 14001 certifications, and its technology has been used in over 100,000 surgical procedures worldwide.
The company operates an exclusively distributor-led go-to-market model, selling through a network of regional and country-specific exclusive distributors covering 65+ markets across Europe, the Middle East, Asia Pacific, Africa, and Latin America. It supplements its product with a substantial clinician-education ecosystem: 31 clinical publications, 66 case studies, 77 archived webinars, the EdgeX blended-learning platform, and a global 'EthOss Case Studies' Facebook community of over 11,000 clinicians, plus a patient-facing 'Find Your EthOss Clinic' interactive map that funnels patients to certified practitioners. EthOss reported net sales of approximately £5.4 million for the year ending July 2025 with a staff of ~16. In Q1 2026, Swedish Nasdaq-listed industrial conglomerate Lifco AB acquired a majority stake, consolidating EthOss into Lifco's Business Area Dental segment.
EthOss Regeneration firmographics
Firmographics- Name
- EthOss Regeneration
- Legal name
- Ethoss Regeneration Ltd
- Website
- https://ethoss.dental
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EthOss Regeneration is a UK medical device company that develops a 100% synthetic 65% β-TCP / 35% calcium sulphate bone graft material for dental implant surgery, sold via exclusive distributors in 65+ markets to clinicians and oral surgeons globally.
- Ownership category
- akta.pro rank
EthOss Regeneration industry classification
Industry- Product category
- Dental Bone Graft Biomaterials
- NAICS
- Dental Equipment and Supplies Manufacturing (339114), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Dental Equipment & Supplies (3843), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Bone Grafting & Ridge Augmentation (GBR/Sinus Lift) (HLABACAG), Dental Implant Surgery & Bone Grafting (HLABAEAB), Dental Implant Placement (Surgical Implantology) (HLABACAE)
Keywords
Where EthOss Regeneration is headquartered
LocationHeadquarters
- HQ city
- Silsden
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
EthOss Regeneration business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Operations, Personnel, Supply Chain
Revenue model
- Product Sales (Synthetic Bone Graft Material): EthOss generates revenue through the sale of its synthetic bone graft material to dental clinicians and oral surgeons globally via its distributor network. The product is sold in unit sizes of 0.25cc, 0.5cc, and 1cc syringes. Revenue for the year ending July 2025 was approximately £5.4 million.
- Practice/Specialist Programme: EthOss enrols dental practices as certified specialists on its interactive patient-facing clinic map, which drives patient referrals to practitioners using EthOss, indirectly supporting product revenue through increased demand.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Pricing not publicly disclosed; quote-based distribution model. |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
EthOss Regeneration product offering
Product offeringCore offering
EthOss develops, manufactures, and sells a 100% synthetic bone graft material for dental implant surgery, combining 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate. The product is delivered in ready-to-use syringe applicators in three sizes (0.25cc, 0.5cc, and 1cc), mixed with standard sterile saline at the point of use. The calcium sulphate component sets in situ to form an integrated cell-occlusive barrier that eliminates the need for a separate collagen membrane, and the material is fully resorbed and replaced by the patient's own host bone within 6–12 months.
Product overview
EthOss Regeneration offers a single flagship product - the EthOss Bone Graft Material - supported by a suite of clinical education and training resources. The core product is a 100% synthetic bone graft material designed for dental implant surgery, featuring an innovative combination of beta tricalcium phosphate and calcium sulfate that eliminates the need for separate collagen membranes. The company supplements its product offering with EdgeX (a blended learning experience), an extensive publications library of clinical research, virtual seminar archives, and a collection of case study books. The product is delivered in syringe applicators in three sizes (0.25cc, 0.5cc, 1cc) and is sold through a global network of exclusive distributors in over 65 markets worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- EthOss Bone Graft: The company's flagship synthetic bone graft material for dental implant surgery, combining 65% beta tricalcium phosphate and 35% calcium sulphate.
- EdgeX
Products and services
- EthOss Bone Graft Material A 100% synthetic alloplastic bone graft biomaterial for dental implant and oral surgery, combining 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate in a syringe applicator. The calcium sulphate sets in situ to form a built-in cell-occlusive membrane, eliminating the need for a separate collagen membrane, and the material is fully resorbed and replaced by host bone within 6-12 months. Available in 0.25cc, 0.5cc, and 1cc sizes; sold to dental clinicians and oral surgeons globally via exclusive distributors in over 65 markets.
Quantifiable outcome
- 50% resorbed and replaced by new host bone at 12 weeks; 85% at 33 weeks
- +4 more outcomes
Companies that use EthOss Regeneration
Customer profileNamed customers9 records
Segments2 records
Ideal customer profiles2 records
EthOss Regeneration technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
EthOss Regeneration partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Global Distributor NetworkcoreEthOss operates through a network of exclusive distributors across over 65 markets globally. Key distributors include MegaGen Benelux, Southern Implants (Greece, France, UAE, South Africa, Australia), Swallow Dental Supplies (UK), Dental Shop Albania, Zantomed GmbH (Germany), and many others covering Europe, Africa, Asia, Middle East, Australasia, and South America. Distributors receive extensive training, sales and marketing support, and access to clinical speakers.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
EthOss Regeneration competitors and assessment
Company assessmentDirect peers
- botiss biomaterials: German dental bone graft and regenerative materials company offering alloplast, xenograft, and allograft products plus membranes. Direct competitor to EthOss in the synthetic/alloplast dental regeneration segment across European and global markets.
- Geistlich Pharma: Swiss manufacturer of Bio-Oss (bovine xenograft) and Bio-Gide collagen membrane, the gold-standard dental bone graft and membrane combination against which EthOss directly competes. Highly comparable product category, customer base (implantologists and oral surgeons), and clinical use cases.
Broad incumbents
- Dentsply Sirona: Largest dedicated dental equipment and materials manufacturer globally, with a regenerative and surgical solutions portfolio. Overlaps with EthOss in dental bone grafting and surgical consumables sold through dental distribution.
- Henry Schein: Largest dental distributor globally with a growing portfolio of own-brand and partner dental regenerative products. Comparable go-to-market through dental professionals and specialist practices.
- Straumann Group: Swiss global dental implant leader (Straumann, Neodent, Medentika) with an expanding regenerative portfolio. Competes with EthOss indirectly via integrated implant-plus-graft solutions and has the scale and KOL access that EthOss lacks.
- Medtronic (Dental and Craniomaxillofacial): Diversified medical device leader with a dental and CMF regenerative materials portfolio including allograft and synthetic bone graft substitutes. Adjacent competitor with deep regulatory and clinical infrastructure.
- Septodont: French global leader in dental pharmaceuticals and biomaterials, with bone graft substitute and regenerative products sold to dentists and oral surgeons. Comparable customer base and dental specialty channel.
- Zimmer Biomet: Global orthopedic and dental player with a dental regenerative materials business (including RegenerOss allograft and synthetic bone graft substitutes). Comparable product category with significantly broader resources.
- Envista Holdings (Kerr Dental): Dental-focused parent of Kerr, Nobel Biocare, and Ormco. Competes in dental implant workflows including bone grafting and regenerative materials distributed through dental channels globally.
Emerging players
- Salvin Dental Specialties: US-based dental surgical and regenerative products specialist selling bone graft materials, membranes, and surgical kits to implantologists. Comparable niche focus on the same clinician base but with a primarily xenograft/allograft portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
EthOss Regeneration social profiles
Digital presenceEthOss Regeneration compliance and trust
Trust signalCompliance3 records
EthOss Regeneration financial estimates
Financial estimateRevenue estimate
Valuation estimate
EthOss Regeneration leadership team
Management profileNumber of profiles
Profiles1 record
EthOss Regeneration funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EthOss Regeneration M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EthOss Regeneration
What does EthOss Regeneration do?
EthOss develops, manufactures, and sells a 100% synthetic bone graft material for dental implant surgery, combining 65% beta tricalcium phosphate (β-TCP) with 35% calcium sulphate. The product is delivered in ready-to-use syringe applicators in three sizes (0.25cc, 0.5cc, and 1cc), mixed with standard sterile saline at the point of use. The calcium sulphate component sets in situ to form an integrated cell-occlusive barrier that eliminates the need for a separate collagen membrane, and the material is fully resorbed and replaced by the patient's own host bone within 6–12 months.
Is EthOss Regeneration a public or private company?
EthOss Regeneration is a private company. It is classified as corporate owned and is currently operating.
When was EthOss Regeneration founded?
EthOss Regeneration was founded in 2013. It employs 1 to 10 people.
Where is EthOss Regeneration based?
EthOss Regeneration is headquartered in Silsden, United Kingdom, in the Europe region.
How does EthOss Regeneration make money?
Two revenue lines are on record. Product Sales (Synthetic Bone Graft Material) is the primary driver. The others are practice/Specialist Programme.
Who are EthOss Regeneration's main competitors?
Direct peers on record are botiss biomaterials and Geistlich Pharma. Broad incumbents are Dentsply Sirona, Henry Schein, Straumann Group, Medtronic (Dental and Craniomaxillofacial), Septodont, Zimmer Biomet and Envista Holdings (Kerr Dental). Salvin Dental Specialties is listed as an emerging player.
Does EthOss Regeneration have an API?
No public API is recorded for EthOss Regeneration.
What industry is EthOss Regeneration in?
EthOss Regeneration's product category is Dental Bone Graft Biomaterials. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLABACAG, Bone Grafting & Ridge Augmentation (GBR/Sinus Lift). Its NAICS code is 339114 and its SIC code is 3843.